ArticleMolecular biology reports2026
Ferroptosis-inflammasome crosstalk contributes to hyperglycemia-induced neuronal injury and is modulated by the ferroptosis inhibitor UAMC-3203.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHyperglycemia associated with diabetes and its neurological complications is strongly linked to oxidative stress and chronic inflammation; however, the contribution of ferroptosis to this process remains incompletely understood. Ferroptosis is an iron-dependent form of regulated cell death characterized by lipid peroxidation and glutathione depletion and has recently been implicated in neurodegenerative disorders and diabetic neuropathy. Nevertheless, the interaction between ferroptosis and inflammasome signaling in hyperglycemia-induced neuronal injury remains unclear. This study aimed to investigate the role of ferroptosis in hyperglycemia-induced neuronal damage and to evaluate the potential protective effects of the ferroptosis inhibitor UAMC-3203.
methodsSH-SY5Y cells differentiated with retinoic acid were exposed to normoglycemic or hyperglycemic conditions and treated with UAMC-3203. Expression levels of ferroptosis-related proteins (GPX4, ACSL4), inflammatory mediators (NLRP3, Caspase-1), and the antioxidant transcription factor Nrf2 were analyzed by Western blotting. Lipid peroxidation and antioxidant status were assessed by measuring malondialdehyde (MDA) and glutathione (GSH), while apoptosis was evaluated using Annexin V/PI flow cytometry.
resultsHyperglycemia suppressed GPX4 expression while increasing ACSL4, lipid peroxidation, and NLRP3 inflammasome activation, indicating enhanced ferroptotic and inflammatory stress. UAMC-3203 reduced lipid peroxidation, restored GSH levels, and markedly suppressed NLRP3 expression, particularly at higher concentrations. However, high-dose UAMC-3203 increased apoptotic cell death, suggesting a shift toward alternative cell death pathways when ferroptosis is inhibited.
conclusionsCollectively, these findings indicate that hyperglycemia induces neuronal injury through a ferroptosis-associated inflammatory signaling axis and that targeting ferroptosis may represent a promising therapeutic strategy for diabetes-related neuronal damage.
Indexed as
Identifiers
42113064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.